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Abstract
Purpose: The purpose of this study was to evaluate safety,
pharmacokinetics, pharmacodynamics, and preliminary antitu-
mor efﬁcacy of ARGX-110, a glyco-engineered monoclonal anti-
body, targeting CD70, in patientswithCD70 expressing advanced
malignancies.
Experimental Design:Dose escalation with a sequential 3þ3
design was performed in ﬁve steps at the 0.1, 1, 2, 5, and 10
mg/kg dose levels (N ¼ 26). ARGX-110 was administered
intravenously every 3 weeks until progression or intolerable
toxicity. Dose-limiting toxicity was evaluated in the 21 days
following the ﬁrst ARGX-110 administration (Cycle 1). Sam-
ples for pharmacokinetics and pharmacodynamics were
collected.
Results: Dose-limiting toxicity was not observed and the max-
imum tolerated dose was not reached. ARGX-110 was generally
well tolerated, with no dose-related increase in treatment-emer-
gent adverse events (TEAE). Themost common TEAEwere fatigue
and drug related infusion-related reactions (IRR). Of the 20 SAEs
reported, ﬁve events, all IRRs, were considered related to ARGX-
110. ARGX-110 demonstrates dose proportionality over the dose
range 1 to 10 mg/kg, but not at 0.1 mg/kg and a terminal half-
life of 10 to 13 days. The best overall response was stable disease
(14/26) in all 26 evaluable patients with various malignancies
and the mean duration of treatment was 15 weeks. No dose–
response related antitumor activity was observed, but biomarker
readouts provided signs of biological activity, particularly in
patients with hematologic malignancies.
Conclusions: This dose-escalation phase I trial provides evi-
dence of good tolerability of ARGX-110, pharmacokinetics, and
preliminary antitumor activity at all dose levels in generally
heavily pretreated patients with advanced CD70-positive malig-
nancies. Clin Cancer Res; 23(21); 6411–20. 2017 AACR.
Introduction
With only limited expression in normal tissues, CD70 is an
increasingly recognized target for the development of anti-
body-based therapies (1–4). CD70, a member of the tumor
necrosis factor receptor ligand family, is transiently expressed
on activated B and T cells, and mature dendritic cells (5–9). It
interacts with its receptor CD27 that is more widely expressed
on various subsets of B and T cells, and on a subset of natural
killer (NK) cells. CD70-mediated effects are generally based on
activation of CD27-associated signaling pathways. CD27 acti-
vation results in enhanced activity of NF-kB and Jun amino-
terminal kinase (JNK) pathways, which have been implicated
in differentiation, activation, and survival of B and T cells (2, 8,
10–13). Upon binding of CD70 to CD27, a soluble form of
CD27 (sCD27) is released. High sCD27 levels have been
detected in patients with autoimmune disease and cancer.
Chronic expression of CD70 leads to lethal immune suppres-
sion in mice (7), and to exhaustion of effector memory T cells
in B-NHL (14).
CD70 is strongly expressed in a large spectrum of solid tumors
and hematologic malignancies, such as renal, pancreatic, lung,
ovarian carcinomas, and lymphomas (1, 15–17). Although
CD70–CD27 signaling in the immune system can lead to induc-
tion of both immunity and tolerance, its roles in the microenvi-
ronment of various tumors are less clear (2, 8, 9). Initially, CD70
expression on solid tumors was believed to be an epiphenome-
non of tumor biology. Recent evidence suggests that it may also
play a role in the evasion of immune surveillance by malignant
cells as observed for programmed death-1 (PD1) and its ligand
(PD-L1), which are frequently upregulated by a range of tumor
types (18). Interestingly, tumor cells expressingCD70 increase the
frequency of T-regulatory cells (Tregs) and activate them in the
tumor microenvironment, thereby creating an immunosuppres-
sivemicroenvironment (19–21). In addition, in some tumors like
B-cell malignancies, CD70 is co- and overexpressed with its
receptor CD27, leading to autocrine-paracrine signaling of the
tumor cells and resulting in its survival and proliferation (13, 22).
Targeting CD70 may therefore be associated with a clinically
beneﬁcial therapeutic index.
ARGX-110 is a next-generation germlined (reverse mutation to
human germline sequences) mAb that binds to human CD70
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with picomolar afﬁnity and blocks CD70–CD27 signaling (23). It
has been modiﬁed by afucosylation of the Fc region to induce
enhanced antibody-dependent cell-mediated cytotoxicity
(ADCC) using POTELLIGENT technology (24, 25), to provide
a potent mAb for use in cancer therapy. ARGX-110 has multiple
mechanisms of action, including blocking CD70–CD27 signal-
ing, which is thought to inhibit evasion of tumor immune
surveillance by reducing the number of Tregs in the tumor
microenvironment as well as to inhibit tumor proliferation and
survival, whereas its effector functions being complement-depen-
dent cytotoxicity (CDC), antibody-dependent cellular phagocy-
tosis (ADCP), and the enhanced ADCC are responsible for the
efﬁcient killing of CD70-expressing tumor cells (23).
We report results from a ﬁrst-in-human multicenter phase I
study of ARGX-110 in generally heavily pretreated patients with
advanced solid tumors and hematologic malignancies that
express the CD70 antigen. This study evaluated the safety, phar-
macokinetics, pharmacodynamics, and preliminary antitumor
efﬁcacy.
Population and Methods
Patients and study design
The study was an open-label, non-randomized, multicenter
study. The primary objective was to determine the maximum-
tolerated dose (MTD) and establish the recommended phase II
dose (RP2D) of ARGX-110 and the secondary objectives were to
investigate pharmacokinetics (PK), biomarkers of drug activity,
and preliminary evidence of antitumor efﬁcacy.
The trial (EudraCTnumber 2012-005046-38)was conducted in
compliance with the Declaration of Helsinki and the Internation-
al Conference on Harmonization Good Clinical Practices Guide-
lines. The clinical study protocol and its amendments, informed
consent documents, and any other appropriate study-related
documents were reviewed and approved by the applicable region-
al review boards or ethic committees. All authors had access to the
primary clinical data.
Patients of 18 years of age with solid tumor or lymphoma
positive for the CD70 antigen in archived or fresh tumor tissue, as
determined by immunohistochemistry (>10%) or ﬂuorescent-
activated cell sorting (FACS) for leukemia, were eligible. The
malignancy had to be refractory to or relapsing after standard
therapy (including autologous stem cell transplantation, ASCT).
Additional eligible and exclusion criteria are described in Sup-
plementary Methods.
Treatment and rationale for dose selection
The starting dose (0.1 mg/kg) was lower than the human
equivalent dose (HED) at 9.7 mg/kg calculated from the no-
observed-adverse-effect level (NOAEL) determined in cynomol-
gus monkeys (30 mg/kg). It was predicted to result in a human
AUC approximately 700-fold lower than the AUC associated with
the NOAEL.
The dose-escalation phase used a sequential 3þ3 design for
determination of MTD. The recommended phase II dose was
the dose level below the MTD if reached. Patients received
ARGX-110 at doses of 0.1, 1, 2, 5, and 10 mg/kg once every 3
weeks (on day 1 of a 21-day cycle) until they developed
progressive disease (PD) or intolerable drug-related toxicity,
or withdrew consent.
For the ﬁrst dose cohort of 0.1mg/kg, the ﬁrst two patients who
received ARGX-110 experienced IRRs during their ﬁrst infusion.
This led to the introduction of pre-medication to minimize the
risk of IRRs in a protocol amendment. Premedications were
administered before each intravenous administration of ARGX-
110 included acetaminophen (1,000 mg) and antihistamine
(diphenhydramine 50 mg equivalent) was taken orally 12 and
0.5 hours before infusion, and IV glucocorticoid (hydrocortisone
100 mg equivalent) 0.5 hour before infusion. Variance based on
institutional practice was acceptable once discussed with the
sponsor.
Safety
Patients were hospitalized to receive the ﬁrst dose of ARGX-110
and observed for the development of adverse events (AE) accord-
ing to institutional practice for a minimum of 24 hours. Doses in
later cycles were administered in the outpatient setting. After the
ﬁrst ARGX-110 administration at each dose level, patients were
observed for signs of toxicity for 24 hours before discharge; the
observation period was 4 hours after all other doses. At each
dose level, patients were evaluated for toxicity during treatment
and at 30 and 60 days after the last ARGX-110 infusion. All AEs
were followed up until resolution or 60 days from the last dose of
ARGX-110.
Dose-limiting toxicities (DLT) were deﬁned as drug-related
grade 3 or 4 clinical AEs, severity graded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events [NCI-CTCAE] version 4.03, occurring
21 days (cycle 1) following the ﬁrst ARGX-110 administra-
tion (except inadequately treated nausea/vomiting). Grade
3 thrombocytopenia without hemorrhage, grade 3 neutrope-
nia without fever, and grade 4 neutropenia lasting 7 days
or less did not qualify as a DLT. For acute infusion
reaction or cytokine release syndrome, a DLT was deﬁned
as grade 4 drug-related toxicity or grade 3 that could not be
resolved by infusion-rate reduction or interruption, or sup-
portive care.
Translational Relevance
With only limited expression in normal tissues and strong
expression on tumor cells, CD70 is an attractive target for
antibody-based therapy. This report describes the ﬁrst-in-
human experience of ARGX-110 in patients with advanced
solid tumors and hematologicmalignancies expressing CD70.
Glyco-engineered ARGX-110 blocks CD70–CD27 signaling,
which is thought to inhibit evasion of tumor immune sur-
veillance as well as inhibiting tumor cell proliferation and
survival, whereas its effector functions being complement-
dependent cytotoxicity (CDC), antibody dependent cellular
phagocytosis (ADCP), and enhanced ADCC efﬁciently kill
CD70-expressing tumor cells. No DLTs were observed and no
MTD was reached. Stable disease with mean duration of 3.7
months was observed in 53.8% of the generally heavily pre-
treated patients andmeanduration of treatmentwas 15weeks.
Biomarker readouts provided signs of biological activity, par-
ticularly in patients with hematologic malignancies. These
results support the continued clinical development of
ARGX-110 in various tumor types.
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Assessments
A full clinical history and clinical and biological evaluation,
including blood counts, differential serum chemistry, renal, and
hepatic function measurement, was carried out. Serum samples
were collected from all patients pre-administration cycle 1, day 1
(C1D1), and then on days 2, 8, and 15 after administration of the
ﬁrst dose of cycle 1, pre- and post-dose for subsequent cycles, and
at the 30- and 60-day follow-up (FU30 and FU60, respectively)
visits to determine serum concentrations of ARGX-110 using a
validated ELISA.
Exploratory pharmacodynamic (PD)markerswere investigated
for ARGX-110 modes of action. CD70 qPCR was performed on
cDNA [optimal blend of oligo(dT) and randomprimers, Bio-Rad]
prepared from RNA extracted from whole blood collected at pre-
C1, 2 and 6 hours post-C1, and then pre-C2 and 2 hours post-C2
and later cycles (Biogazelle Zwijnaarde). Soluble CD27 (sCD27)
in serum (pre- and post-administration C1 and then only pre-
dose) was measured using the PeliKine compact human sCD27
ELISA (Sanquin). A complement activation assay was used to
investigate ability to induceCDCat the same timepoints as sCD27
samples (23). NK cells were counted (BD Biosciences TrueCount
CD45þCD3CD16þCD56þ lymphocytes). B and T lymphocytes
subsets (TriTest CD3/CD19/CD45, BD Biosciences) and regula-
tory T cells (Treg, detected by CD45, CD4, CD25, CD127, CD27,
and the intracellular Foxp3)was investigated byﬂow cytometry in
whole blood pre-treatment for all cycles and followup (FU30 and
FU60 days).
All patients who had completed one cycle of therapy and
undergone at least one scheduled tumor assessment were con-
sidered evaluable for response by the investigators. Tumor
response was recorded as the best response achieved (expressed
as%of baselinemeasurement) for all patients. Patients with solid
tumors were evaluated for response according to RECIST (26) or
the immune-related RECIST (ir-RECIST; ref. 27). Patients with
hematologic malignancies were assessed according to disease-
speciﬁc response evaluation scheme [e.g., Cheson criteria (28),
mSWAT (29)].
Statistical methods
Continuous variables are summarized by descriptive statistics:
number of patients (N), mean, standard deviation (SD), mini-
mum, median, and maximum values. Geometric mean and
coefﬁcient of variation (CV) are presented for PK parameters
when appropriate. Categorical data are summarized by absolute
and relative frequencies (n and %). Statistical analyses were
performed using SAS 9.3 or higher or Graphpad prism v. 7.01.
Results
Patient demographics and baseline characteristics
Between 21 February 2013 and 29December 2014, a total of 26
patients were enrolled and treated in the dose-escalation phase of
the study. Initially six patients in the 0.1 mg/kg cohort, ﬁve
patients in the 1 mg/kg cohort, three patients in the 5 mg/kg
cohort, andﬁvepatients in the10mg/kg cohortwere enrolled. The
ﬁrst two patients from the 0.1 mg/kg cohort experienced IRR,
which led to the introduction of premedication and one patient
was withdrawn prior to cycle 2 for PD. Therefore, three additional
patientswere included andone additional beyond the3þ3 cohort
to allow for investigation of this treatment. A new cohort of 2mg/
kg with seven patients was added to further extend the PK data
after enrollment of ﬁve patients in the 10 mg/kg cohort.
A total of 26 patients (median age 59.5 years, range 22–78)
with advanced malignancies expressing CD70 (22 solid tumors
and 3 hematologic malignancies with target positive biopsies
and one patient with acute myeloid leukemia (AML), where the
malignant cells were CD70 positive by Flow Cytometry, data
not shown) were treated with ARGX-110. 53.8% of the patients
were male, the majority were Caucasian (92.3%) and 72% had
an Eastern Co-operative Oncology Group (ECOG) perfor-
mance status of 1. Most patients had lived with the diagnosis
for one or more years, and had received prior treatment for their
malignancy. Table 1 summarizes the characteristics of the
patients.
The most commonmain reason for treatment termination was
PD (22/26; 84.6%). Reasons for noncompletion of the study was
death (2/26), loss, or refusal to come for follow up (3/26).
Safety and tolerability
Overall, the safety proﬁle of the ﬁve dose cohorts during
dose escalation was comparable, no DLTs and no MTD were
deﬁned.
Treatment emergent AEs (TEAE) were reported in 25 of 26
patients (302 total events) ofwhich theproportionof patientswas
comparable between dose cohorts. TEAEs reported in 15% of the
patients or more (131 events) are listed as preferred term (PT)
in Table 2. The most common events were fatigue (17 events in
17/26 patients), infusion-related reactions (IRR; 21 events, all
considered related, in 10 patients), dyspnea (11 events in eight
patients), andpyrexia (10 events in 8patients) as shown inTable 2
presented per dose cohort. A total of 79/302 events (26.2%) were
considered related to ARGX-110. Themost common related event
was IRRs (21/79 events in 10 patients out of 26; 38.5%) of which
three patients experienced IRR at C1 (two with no premedication
at C1), four patients at C2 or C3 only, and three formore than one
cycle. IRR symptoms included fever, chills, hypoxia, tremor,
nausea, vomiting, hot ﬂashes, anxiety, bronchospasm, dyspnea,
and rash. All IRRs were grade 1 to 2.
Among the 131 events that were observed in 15% patients or
more, 13 events were grade 3 or 4 (four infections, four anemia,
one abdominal pain, three fatigue, and one dyspnea). Three TEAE
of grade 3 in the 0.1 mg/kg cohort were drug related as judged by
the investigators (hypoxia, decreased appetite, and fatigue). No
grade 4 or 5 toxicities were considered related to ARGX-110.
Treatment was interrupted in 7/26 patients and 12 AEs in 10
patients led to dose delays between cycles.
Among other more infrequent toxicities, lung infections, or
pneumonia were reported in ﬁve patients (two grade 3 at 0.1, one
grade 3 at 1, and one grade 2 and one grade 3 at 10 mg/kg).
A total of 20 serious adverse events (SAE) in 10/26patientswere
recorded. Eight eventswere reported at 0.1mg/kg: three IRRevents
of grade 2 (three patients), two grade 3 pneumonias (two
patients), one grade 3 general physical health deterioration, one
grade 3 hemolytic anemia, and one grade 1 pyrexia. Five events
were reported for two patients at 1 mg/kg: one IRR event of grade
2, one grade 5 respiratory failure, one grade 3 artrial ﬁbrillation,
one grade 3 increased blood creatinine, and one grade 3 urinary
tract obstruction. One grade 5 general health deterioration event
was reported for one patient at 2 mg/kg. No SAE were reported at
5 mg/kg. Finally, six SAEs were reported at 10 mg/kg for two
patients: one grade 5 sepsis and two grade 3 edemas (peripheral
and scrotal) in one patient, one grade 3 dyspnea, one grade 2 IRR
and one grade 2 tibia fracture. Of all SAEs reported, only ﬁve
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events, all IRRs,were considered related toARGX-110, all ofwhich
resolved during dose escalation.
A total of 7/26 patients (26.9%) died during the study with the
majority of themwithin 3months after theﬁrst dose of ARGX-110
due to disease progression [5/7 patients (71.4%)]. One patient at
1mg/kg died of respiratory failure and one at 10mg/kg died from
sepsis. Generally, no clear trend could be identiﬁed especially for
the causes of death or the source of the infections. No death was
related to the study treatment as determined by the investigators.
Overall, ARGX-110 showed a good safety proﬁle and was well
tolerated in all ﬁve dose cohorts during dose escalation.
Treatment duration and overall response
All 26 patients were treated with ARGX-110 at cycle 1, with the
number of patients (N) treated with ARGX-110 decreasing over
time. The majority of patients had no dose interruptions (19/26
patients; 73.1%), nor dose delays (16/26 patients; 61.5%). The
mean duration of treatment for all 26 patients was 105.9 days
(15.1 weeks) as indicated in Fig. 1. The number of cycles ranged
from 1 to 23 cycles, with 74.5 weeks until end of treatment (EOT)
being the longest for a mesothelioma patient. This was a 50-year-
old female, who had two lines of chemotherapy with stable
disease (SD) as best response for 6 months before progression,
followed by treatment of 10 mg/kg ARGX-110 with SD as best
response.
Anti-neoplastic activity was observed at all dose-levels. The best
overall response as per investigator review was SD (14/26
patients; 53.8%) as opposed to PD (12/26 patients; 46.2%). The
highest percentage of patients with SD was in the 5 mg/kg cohort
(3/3 patients; 100.0%). This was followed by a total of 4/6
patients (66.7%) in the 0.1 mg/kg cohort and 3/5 patients
(60.0%) in the 1 mg/kg cohort. The 10 mg/kg cohort (2/5
patients; 40.0%) and the 2 mg/kg cohort (2/7 patients; 28.6%)
had the lowest number of patients with SD (Fig. 1). Mean
duration of SD was 3.7 months.
A 58-year-old female, diagnosed with adenoid cystic parotid
carcinoma had lung metastases and PD at the time of enrolment.
She had prior left parotidectomy and radiotherapy, but no sys-
temic cancer treatment was done before she received 1 mg/kg
ARGX-110. At C3D1 she was stable, which remained until the last
cycle 20, when she was progressing and was taken off the study.
A 66-year-old male, diagnosed with papillary renal carcinoma,
received treatment at 0.1mg/kg for 8 cycles before he experienced
hemolytic anemia (SAE), which was resolved within 6 weeks. The
patient had SD during treatment, but was progressing after treat-
ment interruption and before reentering into the study about 5.5
months later as allowed by the protocol. SDwas again recorded at
cycle 11 and the patient wasmaintained in the study until clinical
progression after cycle 12.
Assessments and pharmacokinetics
There were no overall trends in the hematology and biochem-
istry laboratory data over time. Fluctuations were noted, but no
clear dose effect was visible. There was no change in the urinalysis
parameters.
ARGX-110 demonstrated proportionality over the dose range 1
to 10 mg/kg, but not at 0.1 mg/kg (Fig. 2A). The median Cmax in
cycle 1 was 1.6, 21.6, 39.4, 109.0, and 287.0 mg/mL, for the 0.1, 1,
2, 5, and 10mg/kg cohorts, respectively and themedian AUCwas
4072.2, 9036.6, 35845.1, and 72437.8 mg  h/mL for the 1, 2, 5,
and 10mg/kg cohorts, respectively. Themedian t1/2 of ARGX-110
Table 1. Patient demographics and baseline characteristics
Characteristics Total (N ¼ 26)
Age (years) Mean (SD) 57.1 (13.03)
Median [Range] 59.5 [22.0–78.0]
Sex Male 14 (53.8%)
Female 12 (46.2%)
Race Caucasian 24 (92.3%)
Asian 2 (7.7%)
ECOG Grade 0 7 (28.0%)
Grade 1 18 (72.0%)
Missing 1
Time since cancer diagnosis (years) <1 year 2 (7.7%)
>1–5 years 18 (69.2%)
>5 years 6 (23.1%)
Prior cancer treatments (%) Chemotherapy 84.2
Immunotherapy 11.5
Biological therapy 15.4
TKI therapy 15.4
Other targeted therapy 3.8
Abbreviations: N, number of patients; TKI, tyrosine kinase inhibitor.
Table 2. Treatment emergent adverse events (TEAE) in 15% of patients by preferred term
ARGX-110 every 3 weeks
0.1 mg/kg
(N ¼ 6)
1 mg/kg
(N ¼ 5)
2 mg/kg
(N ¼ 7)
5 mg/kg
(N ¼ 3)
10 mg/kg
(N ¼ 5)
Total
(N ¼ 26)
n, N n, N n, N n, N n, N n, N
Fatigue 4, 4 (66.7%) 4, 4 (80.0%) 4, 4 (57.1%) 2, 2 (66.7%) 3, 3 (60.0%) 17, 17 (65.4%)
IRR 13, 4 (66.7%) 1, 1 (20.0%) 5, 3 (42.9%) 1, 1 (33.3%) 1, 1 (20.0%) 21, 10 (38.5%)
Dyspnea 3, 2 (33.3%) 1, 1 (20.0%) 1, 1 (14.3%) 3, 2 (66.7%) 3, 2 (40.0%) 11, 8 (30.8%)
Pyrexia 2, 2 (33.3%) 4, 3 (60.0%) 0, 0 1, 1 (33.3%) 3, 2 (40.0%) 10, 8 (30.8%)
Decreased appetite 4, 2 (33.3%) 0, 0 4, 3 (42.9%) 2, 2 (66.7%) 0, 0 10, 7 (26.9%)
Abdominal pain 5, 3 (50.0%) 2, 2 (40.0%) 0, 0 1, 1 (33.3%) 0, 0 8, 6 (23.1%)
Nausea 1, 1 (16.7%) 2, 2 (40.0%) 1, 1 (14.3%) 2, 1 (33.3%) 1, 1 (20.0%) 7, 6 (23.1%)
Anemia 3, 3 (50.0%) 2, 1 (20.0%) 1, 1 (14.3%) 0, 0 1, 1 (20.0%) 7, 6 (23.1%)
Diarrhea 1, 1 (16.7%) 5, 3 (60.0%) 0, 0 0, 0 1, 1 (20.0%) 7, 5 (19.2%)
Headache 3, 2 (33.3%) 2, 2 (40.0%) 0, 0 1, 1 (33.3%) 0, 0 6, 5 (19.2%)
Edema peripheral 3, 3 (50.0%) 0, 0 0, 0 1, 1 (33.3%) 1, 1 (20.0%) 5, 5 (19.2%)
Cough 1, 1 (16.7%) 1, 1 (20.0%) 2, 2 (28.6%) 1, 1 (33.3%) 0, 0 5, 5 (19.2%)
Back pain 3, 2 (33.3%) 1, 1 (20.0%) 0, 0 1, 1 (33.3%) 0, 0 5, 4 (15.4%)
Myalgia 3, 3 (50.0%) 0, 0 0, 0 1, 1 (33.3%) 0, 0 4, 4 (15.4%)
General physical deterioration 2, 2 (33.3%) 1, 1 (20.0%) 1, 1 (14.3%) 0, 0 0, 0 4, 4 (15.4%)
Nasopharyngitis 0, 0 2, 2 (40.0%) 1, 1 (14.3%) 0, 0 1, 1 (20.0%) 4, 4 (15.4%)
Abbreviations: n, number of events; N, number of patients; %, percentage of patients.
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ranged from 208.7 hours for the 1 mg/kg to 315.3 hours for the
10 mg/kg cohort (8.7–13.1 days; Table 3 and Fig. 2B). Except for
Cmax, calculations could not be appropriately interpreted due to
the sensitivity of the bioanalytical assay not permitting measure-
ment of concentrations of ARGX-110 after the 24-hour time point
in the 0.1 mg/kg dose group [lower limit of quantiﬁcation
(LLOQ) 0.5 mg/mL]. As a result, the terminal elimination phase
is notwell characterized for that dose and t1/2 cannot be estimated
(and thus also not CL, Vd, and AUC¥). The data should be
carefully interpreted because of the limited number of patients
and short observation window. There were no apparent correla-
tions between pharmacokinetic parameters and either clinical
treatment response or adverse events.
CDC was measured by blood sampling predose and 2 hours
after the ﬁrst administration of ARGX-110 for all cohorts. The
serum (containing ARGX-110) was incubated with (CD70þ)
U266 cells that are sensitive to CDC and the amount of lysis
was measured by ﬂow cytometry. Analysis of CDC and Ctrough
at pre-C2 (480 hours) in serum at the same time-point
shows that there was complete lysis by CDC at all doses even
before the next dose (mean Ctrough for dose group 1 mg/kg was
2.4 mg/mL), except for 0.1 mg/kg cohort, where CDC was only
observed 2 hours after the ﬁrst dose (Fig. 2C). This correlates
well with the serum concentrations of ARGX-110 (Fig. 2B),
indicating that for maximal CDC lysis, a serum concentration
of more than 1.6 mg/mL was needed.
The read out of the biomarkers gave some insight in the
mechanisms of action of the drug. Target modulation in cir-
culating normal lymphocytes and tumor cells were followed by
measuring CD70 mRNA levels using qPCR. There was an
overall tendency for decreased CD70 mRNA levels after treat-
ment compared to pre-dose (Fig. 2D). One cutaneous T-cell
lymphoma (CTCL) patient with Sezary syndrome in the 10 mg/
kg cohort showed the highest levels of CD70 measured by
qPCR (31 CNTQ vs. mean around 3 CNTQ for the rest of the
patients) with depletion by 77% already 2 hours after the ﬁrst
dose and remained low until 2 hours after the second ARGX-
110 administration (Fig. 2E). Unfortunately, the patient was off
the study due to non-drug related sepsis after two doses. This
patient also had high levels of sCD27 (>1,000 IU/mL) indi-
cating a high tumor burden, but it remained unchanged after
ARGX-110 administration. Overall, the mean sCD27 levels at
baseline were not signiﬁcantly increased compared to healthy
levels (200–500 U, in-house data) in all cohorts and there was
no major change during treatment.
The mean of regulatory T cells (Tregs) versus CD4þ cell
numbers in whole blood were not altered as shown for pre-
treatment samples C1–C3 when >50% of the patients were still
in the study (Fig. 3A) except for a 22-year-old patient diagnosed
with Hodgkin's lymphoma (HL), who entered the study with
strong CD70 expression but no coexpression of CD27 (data not
shown). The patient had three lines of previous chemotherapy
and ASCT followed by lenalidomide. Before treatment with
1 mg/kg of ARGX-110, high numbers of Tregs could be detected
in the blood (12.7% of total number of CD4þ T lymphocytes).
The frequency dropped to almost normal levels (6% vs. 4% as
found in healthy individuals) after four treatment cycles. After
the patient was taken off the study, the analysis of two addi-
tional blood samples taken in the follow up period (FU) 52
(FU30) and 73 (FU60) days after the last treatment cycle
revealed a rise in circulating Tregs (10% of total number of
CD4þ T cells) whereas the patient did not receive any treatment
at the time (Fig. 3B).
A similar observation was made in one AML patient, who also
had high numbers of circulating Tregs prior to treatment (13%),
which came down after a single administration of ARGX-110 at a
dose of 2 mg/kg (9%, data not shown).
As per investigator information, a 78-year-old female diag-
nosed with stage IIb CTCL in 1997, had a detectable CD3þ/
CD4/CD8 TCRgd malignant clone (12%) in the circulation
and skin lesions on one arm and one leg before enrolment.
She was treated with 0.1 mg/kg ARGX-110 for six cycles and her
skin lesions remained stable, but the circulating malignant
clone was not detectable upon the ﬁrst measurement at cycle
4, which was conﬁrmed again 1 month later, indicating a
complete response in the blood compartment according to the
mSWAT score (29). The patient withdrew consent for personal
reasons.
Figure 1.
Efﬁcacy outcome. Anti-neoplastic
outcomes (compared to baseline
assessments) by investigator review
for patients that completed at least one
cycle of therapy and had undergone at
least one tumor assessment. Each bar
represents one patient and the length
of the bar the duration (weeks) of
treatment until EOT. Patients are
grouped after dose. Patientswith SD as
best response are indicated with a star,
whereas patients with PD are without
symbol. Hematologic malignancies are
in italics. The vertical dotted line
indicates the mean duration of
treatment (weeks). RCC, renal cell
carcinoma; HL (B), Hodgkin's
lymphoma, B-cell; NPC,
nasopharyngeal cancer; CTCL,
cutaneous T cell lymphoma; AML,
acute myeloid leukemia.
Phase I Safety Study of ARGX-110
www.aacrjournals.org Clin Cancer Res; 23(21) November 1, 2017 6415
on February 12, 2018. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 1, 2017; DOI: 10.1158/1078-0432.CCR-17-0613 
No major changes in percentage of CD3þ T cells or CD19þ B
cells of total CD45þ lymphocytes were observed in any of the
cohorts (Fig. 3C and D). For all cohorts, the mean NK cell counts
(Fig. 3E) were not affected during the treatment for any of the
cohorts.
Discussion
In the dose escalation phase of this phase I study of ARGX-
110 in patients with solid tumors and hematologic malignan-
cies, neither DLT nor MTD were observed across ARGX-110
Figure 2.
Pharmacokinetics of ARGX-110 and exploratory pharmacodynamics. A, Dose proportionality for dose normalized AUC0-¥/D (h  mg/mL/mg) for dose groups 1 to
10mg/kg.B,Serumconcentrations ofARGX-110 after one administrationmeasuredbyELISAon immobilizedCD70 for samples at eachdose level. Data are presented
as arithmetic mean (mg/mL) and standard error (SD) on a linear-log scale at the different time points (hours). C, CDC (% lysis) in peripheral blood samples
for each dose level (0.1, 1, 2, 5, and 10mg/kg) at 480 hours (pre-C2 on day 21) plotted against theCtrough (mg/mL) in serumat the same time-point. Dotted line indicate
effective dose 1.6 mg/mL. D, Target modulation in circulating normal lymphocytes and tumor cells was followed by measuring CD70 mRNA levels using
qPCR. Expressed as % change from baseline (pre-C1) after normalization (mean of triplicates) at dose levels 0.1, 1, 2, 5, and 10 mg/kg. E, Target modulation of
circulating clone measured by CD70 mRNA using qPCR in a CTCL patient treated at 10 mg/kg for two cycles as % decrease normalized versus baseline (pre-C1), 2
hours post-C1 (C1D1-2H), 6 hours post C1 (C1D1-6H), pre-C2 and 2 hours post-C2 (C2D1-2H). Expressed as % decrease from baseline (pre-C1) after normalization
(mean of triplicates).
Aftimos et al.
Clin Cancer Res; 23(21) November 1, 2017 Clinical Cancer Research6416
on February 12, 2018. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 1, 2017; DOI: 10.1158/1078-0432.CCR-17-0613 
doses of 0.1 to 10 mg/kg, which has been observed in trials
involving immune targeting antibodies (reviewed by ref. 30).
No dose–response was observed in terms of anti-neoplastic
efﬁcacy or toxicity and the best overall response was SD,
observed in more than half of the patients (53.8%) and mean
duration of treatment was 15 weeks, corresponding to ﬁve
cycles every 3 weeks. The mean duration of SD was 3.7 months
with the longest 14 months.
ARGX-110 was generally well tolerated, and most events were
mild or moderate and easily managed. There were no major
hematologic effects and no effect on the total number of B-, T-,
or NK cells as shown by ﬂow cytometry. Fatigue was the most
common TEAE, followed by IRRs (in 38.5% of patients), which
were observed at all doses anddifferent cycles betweenC1 andC3.
Two patients, who received 0.1 mg/kg ARGX-110 before preme-
dication, experienced IRR. IRRs are frequently observed for mAb
therapeutics with and without glyco-engineering, with, for exam-
ple, an incidence of up to 77% for rituximab (chimeric antibody),
amAb targeting CD20 (31). Similarly, with the afucosylatedmAb
directed against CD20, obinutuzumab, IRRs were found to be the
most frequently reportedAEs, occurring in 86%of patients, and to
be limited to grade 1 or 2 events (32). However, grade 3 events
have been observed in one-ﬁfth of patients in other obinutuzu-
mab studies (33). Hence, the frequency and grading of IRRs after
premedication for ARGX-110 proved to be mild and manageable
(38.5% of patients and grade 1–2).
Among the patients who died due to SAE during the study, one
was a CTCL patient who was admitted to the hospital with life-
threatening sepsis due to multiple cutaneous barrier breaks local-
ized on the tumor lesions. The patient died due to this event,
considered not related to ARGX-110 by the investigator. In
patients with advanced malignancies, infections are of concern
and frequently occur, mainly because of bone marrow suppres-
sion and neutropenia from cytotoxic chemotherapies (34). The
infectious complications of patients with CTCL are of importance
since they are involved in over 50% of deaths in patients with
CTCL (35–37).
Pharmacokinetic analyses of ARGX-110 demonstrated dose
proportionality over the dose range of 1 to 10 mg/kg, but not
at 0.1 mg/kg and a terminal half-life of 10 to 13 days. The
measurement at day 7 (168 hours) was below LLOQ for
the 0.1 mg/kg which may suggest that this dose shows an
increased clearance which could be explained by target-
mediated drug disposition as has been suggested for other
antibodies at lower concentrations (32). Because of the limited
number of patients and short observation window and no
apparent correlations between pharmacokinetic parameters,
and either clinical treatment response or adverse events, fur-
ther investigations should be performed. Because 0.1 mg/kg
did not show complete CDC, 10 mg/kg did not show better
beneﬁts than 5 mg/kg and to create a safety margin, the two
intermediate doses 1 and 5 mg/kg, administered every 3 weeks,
were chosen for future expansion cohorts including solid and
hematologic malignancies.
Target modulation in circulating normal lymphocytes and
tumor cells were followed bymeasuringCD70mRNA levels using
qPCRand thenumber of T, B,NK, andTreg cellsweremeasured by
ﬂow cytrometry. It was not possible to measure CD70 by ﬂow
cytometry after the ﬁrst dose of ARGX-110 so the expression levels
of CD70 on these cells could not be assessed. There was an overall
tendency for decreased CD70 mRNA levels after treatment com-
pared to predose, but no major changes in the numbers after
ARGX-110 treatment in the overall patient population could be
observed as measured by ﬂow cytometry, but individual patients
showed some effects.We cannot draw any conclusions from these
data, but need to further explore the effects of ARGX-110 on
subtypes of lymphocytes that could express CD70 as well as the
expression of CD70 on tumor cells in the circulation.
Table 3. Pharmacokinetics of ARGX-110 at cycle 1 (21 days after the ﬁrst ARGX-110 administration)
0.1 mg/kg
(N ¼ 6)
1 mg/kg
(N ¼ 5)
2 mg/kg
(N ¼ 7)
5 mg/kg
(N ¼ 3)
10 mg/kg
(N ¼ 5)
Cmax (mg/mL) N 6 5 7 3 5
GM 1.78 22.5 42.6 123.8 288.4
%CV 44.1 32.6 15.6 33.3 13.5
Median 1.61 21.6 39.4 109 287
Terminal rate constant N 0 5 7 3 5
(hours1) GM NA 0.003 0.003 0.002 0.002
%CV NA 39.7 49.7 36.1 26.7
Median NA 0.003 0.003 0.002 0.000
AUC¥ (mg  h/mL) N 0 5 7 3 5
GM NA 4072.2 9036.3 35845.1 72437.8
%CV NA 58.7 41.5 16.4 45.4
Median NA 4959.3 9409.6 32812.0 68095.5
CL (mL/h) N 0 5 7 3 5
GM NA 15.9 15.0 9.7 11.7
%CV NA 53.3 36.9 35.9 34.1
Median NA 12.5 13.7 10.1 11.5
Vd (L) N 0 5 7 3 5
GM NA 4.8 4.8 4.9 4.9
%CV NA 21.0 22.6 38.5 37.2
Median NA 4.9 4.6 4.6 4.2
t1/2 (h) N 0 5 7 3 5
GM NA 208.7 219.9 351.2 291.4
%CV NA 34.0 45.7 33.6 24.8
Median NA 263.1 246.7 368.8 315.3
Abbreviations: AUC¥, area under the serum concentration–time curve from time 0 to ¥; Cmax, maximum concentration; CL, clearance; CV, conﬁdence of variation;
GM, geometric mean; N, number of patients; NA, not applicable since the values are below lower limits of quantiﬁcation (BLLOQ) at Day 7 (168 hours); t1/2, half-life;
Vd, apparent volume of distribution.
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In vitro studies have shown that ARGX-110 binds with high
afﬁnity to different CD70þ cell lines, inhibiting release of IL8 as a
consequence of interfering with the NF-kB pathway and blocking
Treg proliferation and activation (23). Inhibition is dose depen-
dent and at picomolar concentrations. The ADCC potency of
ARGX-110was found to be increased >20-fold comparedwith the
fucosylated form of the antibody, whereas CDC and ADCP
function remained unimpaired when tested with solid and
Figure 3.
Flow cytometry of lymphocytes in peripheral blood. A, Regulatory T cells (Treg) in whole blood (CD45, CD4, CD25, CD127, CD27 and the intracellular Foxp3) versus
CD4þ cellsmeasured inwhole blood. Mean and standard deviation (SD) of pre-C1–C3 as representativemeasurementswhen50% of patients received treatment at
doses 0.1, 1, 2, 5, and 10 mg/kg. B, Treg in a Hodgkin Lymphoma patient at 1 mg/kg measured pretreatment C1–C4 (black circles) and FU30 and FU60 (open circles).
C, Flow cytometry of T cells in whole blood, detected by CD3 and measured as percentage (%) CD3þ T cells of CD45þ lymphocytes. Mean and SD of pre-C1–C3
samples at doses 0.1, 1, 2, 5, and 10 mg/kg. D, Flow cytometry of B-cells in whole blood detected by CD19 and measured as percentage (%) CD19þ B cells of CD45þ
lymphocytes. Mean and SD of pre-C1–C3 samples at doses 0.1, 1, 2, 5, and 10 mg/kg. E, NK cells (CD45þCD3CD16þCD56þ lymphocytes) were counted using ﬂow
cytometry in peripheral blood samples for each dose level (0.1, 1, 2, 5, and 10 mg/kg). Mean and SD.
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hematologic tumor cell lines (23). In the CTCL patient of the
cohort treated with the highest dose of 10 mg/kg, a rapid and
effective depletion of CD70þ cells was achieved as judged on the
results of theCD70qPCR analysis. This patient was suffering from
Sezary syndrome, which is characterized by large numbers of
circulating malignant cells. The patient had the highest qPCR
signal (approximately 31 vs. 3 as found in healthy individuals),
which decreased by 77% after two administration cycles. IHC of
the skin biopsies revealed strong CD70 and CD27 positivity (data
not shown), therefore it is very likely that the circulating malig-
nant clone was target positive explaining the high qPCR signal
prior to treatment (unfortunately no FACS analysis was per-
formed on blood cells). These data suggest an effective depletion
of the Sezary cells, possibly due to enhanced ADCC in combina-
tion with CDC and ADCP.
In the other CTCL patient, the circulating clone could not
be detected after four treatment cycles with 0.1 mg/kg ARGX-
110, resulting in a complete response in the blood compart-
ment. This patient also had strong CD70 and CD27 expression
as shown by IHC. For AML, CLL, WM, and other B-cell malig-
nancies, the coexpression of CD70 with its receptor CD27 on
the tumor cells was described and in vitro studies with primary
cells derived from ALL patients suggests the existence of an
autocrine loop involved in proliferation of the tumor cells (10,
13, 22, 38). This has not been investigated for T-cell malig-
nancies, so at this moment it is not known whether blocking
the CD70–CD27 signaling pathway contributed to the reduc-
tion of circulating tumor cells in the two CTCL patients or if it
was due to ADCC or other mechanisms of action.
Data suggest that CD70 plays a role in tumor evasion of host
immune surveillance by promoting activation (39), proliferation,
and survival of Treg cells in tumors, thereby encouraging tumor
growth (20, 40). Potentially, by blocking CD70–CD27 signaling,
recruitment/activation of Treg cells within the tumor microenvi-
ronment and CD70–CD27-activated growth signals could be
inhibited. An indication for this inhibitory effect on Treg prolif-
eration was obtained in the HL patient. The Reed–Sternberg cell
has the highest CD70 expression as compared to other B-cell
malignancies, whereas at least in Hodgkin's disease derived cell
lines no coexpression of CD27 can be witnessed (41). Our
immunohistology data conﬁrmCD70 expression and the absence
of CD27 for this patient (data not shown). Marshall and collea-
gues demonstrated for this indication the inhibitory activity of
Tregs inﬁltrating the tumor thereby revealing their role in creating
an immunosuppressive environment (42). Higher numbers of
peripheral Tregs have been reported for HL (43, 44) as we have
observed for the HL patient, who was treated with ARGX-110.
After a few treatment cycles the number of Tregs declined steadily
to almost the levels found in healthy individuals, suggesting that
blocking CD70 indeed affects their proliferation. When treatment
was discontinued, Treg numbers increased again, possibly
because of relief of CD70 blockade. A similar observation was
made for the AML patient, where also increased numbers of
regulatory T cells have been reported (45).
The ﬁndings of this dose-escalation phase I trial provide evi-
dence of good tolerability of ARGX-110 and preliminary antitu-
mor activity at all dose levels in generally heavily pretreated
patients with advanced CD70-positive malignancies, warranting
further investigation in a safety expansion study. In summary, the
MTD of ARGX-110 was not reached in the dose-escalation part of
this study. BasedonCDCdata indicating an effective dose at 1mg/
kg andover and to further explore thedose–response relationship,
to create a safetymargin and to cover PK variability, 1 and 5mg/kg
will be further investigated in safety expansion cohorts including
CD70 positive hematologic malignancies and solid tumors to see
which population will beneﬁt.
Disclosure of Potential Conﬂicts of Interest
P. Aftimos is a consultant/advisory board member for Synthon. L. van
Rompaey, A. Hultberg, D. Gandini, H. De Haard, N. Leupin and A. Thibault
hold ownership interest (including patents) in argenx. J. Michot is a consultant/
advisory board member for Bristol-Myers Squibb. K. Silence is a consultant/
advisory board member for SIVA. V. Ribrag is a consultant/advisory board
member for Bristol-Myers Squibb, Epizyme, MSD, Roche, and SERVIER. No
potential conﬂicts of interest were disclosed by the other authors.
Authors' Contributions
Conception and design: C. Rolfo, F. Offner, T. Dreier, K. Silence, H. de Haard,
A. Thibault, A. Awada
Development of methodology: C. Rolfo, M. Moshir, T. Dreier, K. Silence, H. de
Haard, A. Thibault
Acquisition of data (acquired andmanagedpatients, provided facilities, etc.):
P. Aftimos, C. Rolfo, S. Rottey, F. Offner, D. Bron, M. Maerevoet, J.-C. Soria,
M.Moshir, T. Dreier, J.-M.Michot, H. de Haard, V. Ribrag, M. Peeters, N. Leupin
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): P. Aftimos, C. Rolfo, F. Offner, J.-C. Soria, M. Moshir,
T. Dreier, J.-M. Michot, K. Silence, A. Hultberg, D. Gandini, M. Peeters,
A. Thibault, N. Leupin
Writing, review, and/or revision of the manuscript: P. Aftimos, C. Rolfo,
S. Rottey, F. Offner, M. Maerevoet, J.-C. Soria, M. Moshir, T. Dreier, L. Van
Rompaey, K. Silence, A.Hultberg,D.Gandini,H. deHaard, V. Ribrag,M.Peeters,
N. Leupin
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): P. Aftimos,M.Moshir, A.Hultberg, H. deHaard,
A. Awada
Study supervision: C. Rolfo, S. Rottey, M. Maerevoet, J.-M. Michot, K. Silence,
M. Peeters, A. Thibault, N. Leupin
The costs of publication of this articlewere defrayed in part by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received March 2, 2017; revised June 22, 2017; accepted July 26, 2017;
published OnlineFirst August 1, 2017.
References
1. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert
Opin Therap Targets 2008;12:341–51.
2. Boursalian TE, McEarchern JA, Law CL, Grewal IS. Targeting CD70
for human therapeutic use. Adv Exp Med Biol 2009;647:108–19.
In PUBMED; see webpage https://link.springer.com/book/10.1007/
978-0-387-89520-8 to ﬁnd speciﬁcs about this book (Springer
New York).
3. Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S,
et al. CD70: an emerging target in cancer immunotherapy. Pharmacol Ther
2015;155:1–10.
4. Wajant H. Therapeutic targeting of CD70 and CD27. Expert Opin Therap
Targets 2016;20:959–73.
5. Bowman MR, Crimmins M, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S.
The cloning of CD70 and its identiﬁcation as the ligand for CD27. J
Immunol 1994;152:1756–61.
6. Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA. CD70
represents the human ligand for CD27. Int Immunol 1994;6:477–80.
7. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, SchuurhuisDH,Mebius RE,
et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J
Immunol 2003;170:33–40.
Phase I Safety Study of ARGX-110
www.aacrjournals.org Clin Cancer Res; 23(21) November 1, 2017 6419
on February 12, 2018. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 1, 2017; DOI: 10.1158/1078-0432.CCR-17-0613 
8. Nolte MA, Van Olffen RW, Van Gisbergen KP, Van Lier RA. Timing and
tuning of CD27–CD70 interactions: the impact of signal strength in setting
the balance between adaptive responses and immunopathology. Immunol
Rev 2009;229:216–31.
9. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in
immunity and tolerance. J Leukocyte Biol 2011;89:195–203.
10. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand,
CD70, on chronic lymphocytic leukemia B cells. Blood 1995;85:3556–65.
11. Ramakrishnan P, WangW,Wallach D. Receptor-speciﬁc signaling for both
the alternative and the canonical NF-kB activation pathways by NF-kB-
inducing kinase. Immunity 2004;21:477–89.
12. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation.
Curr Opin Immunol 2005;17:275–81.
13. Nilsson A, de Milito A, Mowaﬁ F, Winberg G, Bj€ork O, Wolpert EZ, et al.
Expression of CD27–CD70 on early B cell progenitors in the bonemarrow:
implication for diagnosis and therapy of childhood ALL. Exp Hematol
2005;33:1500–7.
14. Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, et al.
TGF-b upregulates CD70 expression and induces exhaustion of effector
memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 2014;28:
1872–84.
15. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K,
Schubert J. CD70: a new tumor speciﬁc biomarker for renal cell carcinoma.
J Urol 2005;173:2150–3.
16. RyanM,KostnerH,GordonK,DunihoS, SutherlandM,YuC, et al. Targeting
pancreatic and ovarian carcinomas using the auristatin-based anti-CD70
antibody–drug conjugate SGN-75. Br J Cancer 2010;103:676–84.
17. Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K,
et al.Unlocking the potential ofCD70as anovel immunotherapeutic target
for non-small cell lung cancer. Oncotarget 2015;6:13462–75.
18. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment
of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137,
and anti-PD1. J Immunotoxicol 2012;9:241–7.
19. van Gisbergen KP, van Olffen RW, van Beek J, van der Sluijs KF, Arens R,
Nolte MA, et al. Protective CD8 T cell memory is impaired during chronic
CD70-driven costimulation. J Immunol 2009;182:5352–62.
20. Claus C, Riether C, Sch€urch C, Matter MS, Hilmenyuk T, Ochsenbein AF.
CD27 signaling increases the frequency of regulatory T cells and promotes
tumor growth. Cancer Res 2012;72:3664–76.
21. Pardoll DM. The blockade of immune checkpoints in cancer immuno-
therapy. Nat Rev Cancer 2012;12:252–64.
22. HoAW,Hatjiharissi E, Ciccarelli BT, BranaganAR,Hunter ZR, Leleu X, et al.
CD27-CD70 interactions in the pathogenesis of Waldenstr€ommacroglob-
ulinemia. Blood 2008;112:4683–9.
23. Silence K, Dreier T, Moshir M, Ulrichts P, Gabriels SM, Saunders M, et al.
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors
via both enhanced ADCC and immune checkpoint blockade. MAbs
2014;6;523–32.
24. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada
M, et al. The absence of fucose but not the presence of galactose or bisecting
N-acetylglucosamine of human IgG1 complex-type oligosaccharides
shows the critical role of enhancing antibody-dependent cellular cytotox-
icity. J Biol Chem 2003;278:3466–73.
25. SatohM, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-
generation therapeutic antibodies. ExpertOpin Biol Ther 2006;6:1161–73.
26. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al.
New response evaluation criteria in solid tumors: revised RECIST guideline
(version 1.1). Eur J Cancer 2009;45:228–47.
27. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al.
Guidelines for the evaluation of immune therapy activity in solid
tumors: immune-related response criteria. Clin Cancer Res 2009;
15:7412–20.
28. Cheson BD. New staging and response criteria for non-Hodgkin lym-
phoma and Hodgkin lymphoma. Radiol Clin North Am 2008;46:
213–23.
29. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al.
Clinical end points and response criteria in mycosis fungoides and
Sezary syndrome: a consensus statement of the International Society for
Cutaneous Lymphomas, the United States Cutaneous Lymphoma Con-
sortium, and the Cutaneous Lymphoma Task Force of the European
Organisation for Research and Treatment of Cancer. J Clin Oncol
2011;29:2598–607.
30. Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria J-C, Marabelle A.
Challenges of phase 1 clinical trials evaluating immune checkpoint-tar-
geted antibodies. Ann Oncol 2016;27:214–24.
31. Chung CH. Managing premedications and the risk for reactions to infu-
sional monoclonal antibody therapy. Oncologist 2008;13:725–32.
32. Salles G,Morschhauser F, Lamy T,Milpied N, Thieblemont C, Tilly H, et al.
Phase 1 study results of the type II glycoengineered humanized anti-CD20
monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma
patients. Blood 2012;119:5126–32.
33. Freeman C, DixonM, Houghton R, Kreuzer K, Fingerle-Rowson G, Herling
M, et al. Role of CD20 expression and other pre-treatment risk factors in the
development of infusion-related reactions in patients with CLL treated
with obinutuzumab. Leukemia 2016;30:1763–66.
34. Yapici O, Gunseren F, Yapici H, Merdin A, Yaylali €U€U, Merdin FA.
Evaluation of febrile neutropenic episodes in adult patients with solid
tumors. Mol Clinical Oncol 2016;4:379–82.
35. Dalton JA, YagHoward C, Messina JL, Glass LF. Cutaneous Tcell lympho-
ma. Int J Dermatol 1997;36:801–9.
36. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin
Oncol 1999;26:276–89.
37. Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis
fungoides and Sezary syndrome. Jama 1992;267:1354–8.
38. Riether C, Sch€urch CM, B€uhrer ED, Hinterbrandner M, Huguenin A-L,
Hoepner S, et al. CD70/CD27 signaling promotes blast stemness and is a
viable therapeutic target in acute myeloid leukemia. J Exp Med 2017;
214:359–80.
39. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. CD70þ non-
Hodgkin lymphoma B cells induce Foxp3 expression and regulatory
function in intratumoral CD4þ CD25 T cells. Blood 2007;110:
2537–44.
40. Jak M, Mous R, Remmerswaal EB, Spijker R, Jaspers A, et al. Enhanced
formation and survival of CD4þ CD25hi Foxp3þ T-cells in chronic
lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.
41. Gruss H-J, Duyster J, Herrmann F. Structural and biological features of the
TNF receptor and TNF ligand superfamilies: interactive signals in the
pathobiology of Hodgkin's disease. Ann Oncol 1996;7:S19–S26.
42. Marshall NA, Christie LE,Munro LR, CulliganDJ, Johnston PW, Barker RN,
et al. Immunosuppressive regulatory T cells are abundant in the reactive
lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755–62.
43. Bosler DS, DouglasNikitin VK, Harris VN, Smith MD. Detection of
Tregulatory cells has a potential role in the diagnosis of classical Hodgkin
lymphoma. Cytometry B Clin Cytom 2008;74:227–35.
44. Barath S, Aleksza M, Keresztes K, Toth J, Sipka S, Szegedi G, et al. Immu-
noregulatory T cells in the peripheral blood of patients with Hodgkin's
lymphoma. Acta Haematol 2006;116:181–5.
45. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud . Intensive chemo-
therapy for acute myeloid leukemia differentially affects circulating TC 1,
TH 1, TH 17 and T REG cells. BMC Immunol 2010;11:1–12.
Clin Cancer Res; 23(21) November 1, 2017 Clinical Cancer Research6420
Aftimos et al.
on February 12, 2018. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 1, 2017; DOI: 10.1158/1078-0432.CCR-17-0613 
2017;23:6411-6420. Published OnlineFirst August 1, 2017.Clin Cancer Res 
  
Philippe Aftimos, Christian Rolfo, Sylvie Rottey, et al. 
  
ARGX-110 in Advanced Malignancies
Phase I Dose-Escalation Study of the Anti-CD70 Antibody
  
Updated version
  
 10.1158/1078-0432.CCR-17-0613doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2017/08/01/1078-0432.CCR-17-0613.DC1
Access the most recent supplemental material at:
  
  
  
  
  
Cited articles
  
 http://clincancerres.aacrjournals.org/content/23/21/6411.full#ref-list-1
This article cites 45 articles, 15 of which you can access for free at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/23/21/6411
To request permission to re-use all or part of this article, use this link
on February 12, 2018. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst August 1, 2017; DOI: 10.1158/1078-0432.CCR-17-0613 
